Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: Perspectives and issues on policy-guided health care

Pharmacotherapy

Volumn 28, Issue 5 PART 2, 2008, Pages

  Arbuckle, Rebecca B ^a   Griffith, Niesha L ^b   Iacovelli, Lew M ^c   Johnson, Philip E ^d   Jorgenson, James A ^e   Kloth, Dwight D ^f   Lucarelli, Charles D ^g   Muller, Raymond J ^g  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MOSES CONE HEALTH SYSTEM   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anemia; Centers for Medicare and Medicaid Services; CMS; Darbepoetin alfa; Epoetin alfa; Erythropoiesis stimulating agents; ESAs; Guidelines; National coverage determination; NCD; Pharmacists' role

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD CLOTTING DISORDER; BLOOD DISEASE; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HEALTH CARE POLICY; HEMOGLOBIN DETERMINATION; HUMAN; MEDICARE; OVERALL SURVIVAL; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

EID: 42949159966     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.5supp.1S     Document Type: Review

References (33)